How to Fight a Genetic Testing Denial from Your Health Insurance

Genetic testing denials are among the most frustrating insurance fights patients face. Whether you've been denied a BRCA panel after a breast cancer diagnosis, tumor profiling that could guide your chemotherapy, prenatal cell-free DNA screening (NIPT), or minimal residual disease (MRD) monitoring, the rejection often arrives with vague language about "not medically necessary" or "experimental." In reality, most genetic tests are backed by ironclad clinical guidelines from organizations like the National Comprehensive Cancer Network (NCCN), the American College of Obstetricians and Gynecologists (ACOG), and the U.S. Preventive Services Task Force (USPSTF). Insurers deny these tests not because the science is weak, but because genetic testing is expensive and many plans rely on third-party benefit managers—Avalon, eviCore, Optum Genetic, Carelon—who apply narrow, outdated criteria or simply hope you won't appeal. This guide will show you which guidelines and policy citations overturn the most common denials, and how to structure an appeal that forces your insurer to reverse course.

---

Why Insurers Deny Genetic Testing

1. "Does not meet medical necessity criteria"

This is the catchall. The insurer (or its benefit manager) claims your personal history, family history, age at diagnosis, or tumor characteristics don't rise to the threshold in their internal policy. Often that policy lags 2–5 years behind current NCCN or ACOG guidelines, or it misinterprets them—requiring, for example, three affected relatives when NCCN requires only two, or excluding patients with breast cancer diagnosed at age 46 when the guideline cutoff is ≤50.

2. "Test is investigational / experimental / not proven"

Common for tumor profiling (FoundationOne CDx, Guardant360, Tempus), MRD monitoring (Signatera, Guardant Reveal), and whole-exome/whole-genome sequencing. Insurers label next-generation sequencing "experimental" even when the FDA has approved the test as a companion diagnostic and CMS has issued a National Coverage Determination mandating payment.

3. "More extensive than necessary; single-gene test sufficient"

You're denied a multi-gene hereditary cancer panel (Invitae, Myriad MyRisk, Ambry) and told to get BRCA1/2 only. This ignores NCCN guidance, which since 2019 has recommended multi-gene panels as first-line testing for most patients meeting any hereditary-cancer criterion, because genes like PALB2, ATM, CHEK2, and mismatch-repair genes carry actionable management implications and single-gene testing misses 40–60 % of pathogenic variants.

4. "Patient does not meet high-risk criteria" (NIPT / carrier screening)

For prenatal testing: insurer states that cell-free DNA screening (NIPT) is covered only for advanced maternal age (≥35) or other "high-risk" factors, citing outdated 2012–2016 guidance. ACOG Committee Opinion #226 (reaffirmed 2020) and Practice Bulletin #232 explicitly state that cfDNA screening should be offered to all pregnant patients regardless of risk category. For carrier screening, insurers may limit reimbursement to a short list of conditions (cystic fibrosis, sickle cell, Tay-Sachs) when ACOG #691 endorses expanded pan-ethnic carrier screening.

5. "Prior authorization / genetic counseling not obtained"

Some plans require pre-authorization or genetic-counselor involvement before ordering. This is a procedural denial and is often the easiest to fix on appeal if the test was clinically appropriate—you simply document that the ordering provider is qualified (oncologist, maternal-fetal medicine specialist, certified genetic counselor) or that emergent clinical circumstances (rapidly progressive cancer, limited treatment window) made pre-authorization impractical.

---

The Citations Insurers Respect

When you appeal, you must anchor your argument in named, versioned guidelines and policy statements. Insurers' medical directors are required to follow these standards, especially when they represent the consensus of national specialty societies. Do not let your appeal stay abstract ("my doctor says I need this test"). Name the source, the year, and—when possible—the specific criterion number.

NCCN Guidelines: Genetic/Familial High-Risk Assessment

• NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (current version, e.g., v3.2024)

Lists dozens of personal and family-history criteria (labeled BOP-1, BOP-2, BOP-A, etc.) that constitute automatic indications for germline testing. Examples: breast cancer diagnosed ≤45 years; triple-negative breast cancer ≤60; ovarian/fallopian-tube/primary-peritoneal cancer at any age; pancreatic cancer with Ashkenazi Jewish ancestry; ≥2 breast primaries; male breast cancer; ≥3 relatives with breast/ovarian/pancreatic/prostate cancer; known familial pathogenic variant. NCCN explicitly recommends multi-gene panel testing, not BRCA-only.

• NCCN Guidelines: Genetic/Familial High-Risk Assessment: Colorectal (e.g., v2.2024)

Criteria for Lynch syndrome and other hereditary CRC syndromes (COL-A through COL-F). Key triggers: colorectal or endometrial cancer diagnosed <50; MSI-high or loss of MMR protein expression on tumor immunohistochemistry; ≥1 first-degree relative with Lynch-associated cancer and one diagnosis <50; Amsterdam II criteria; meeting revised Bethesda guidelines.

• NCCN tumor-specific guidelines (Colon, Rectal, Uterine, Non–Small Cell Lung, Melanoma, Prostate, etc.)

Mandate universal tumor testing (MSI/MMR in all colorectal and endometrial cancers; PD-L1, ALK, EGFR, ROS1, BRAF, KRAS, NTRK, MET, RET, HER2 in advanced NSCLC; BRAF/NRAS/KIT/PD-L1/NTRK in melanoma). These guidelines are updated 1–3 times per year; always cite the current version when arguing that biomarker testing is standard of care.

USPSTF BRCA-Related Cancer Screening (2019, Grade B)

The U.S. Preventive Services Task Force gives a B recommendation (moderate net benefit) for risk assessment, genetic counseling, and if indicated BRCA1/2 testing in women with personal or family history of breast, ovarian, tubal, or peritoneal cancer, or ancestry associated with deleterious BRCA mutations (Ashkenazi Jewish, among others). Under the Affordable Care Act §2713 and its implementing regulation 45 CFR §147.130, non-grandfathered health plans must cover services with a USPSTF A or B recommendation without cost-sharing (no copay, no deductible) when delivered by an in-network provider. This means that for qualifying women, BRCA counseling and testing are a mandated preventive benefit.

ACOG Guidance (Obstetrics & Gynecology)

• Committee Opinion #226 (reaffirmed 2020) / Practice Bulletin #232: Screening for Fetal Chromosomal Abnormalities

Cell-free DNA (cfDNA) prenatal screening—NIPT—should be offered to all pregnant patients, regardless of maternal age or other risk factors. This supersedes older guidance that restricted NIPT to high-risk pregnancies.

• Committee Opinion #691 (2017, reaffirmed 2019): Carrier Screening for Genetic Conditions

Both ethnicity-based and expanded pan-ethnic carrier screening are acceptable strategies. Insurers cannot limit reimbursement to a legacy "basic" panel when contemporary practice and laboratory standards include 100+ conditions.

• Committee Opinion #693 / #690: Counseling About Genetic Testing and Results

Standards for informed consent, genetic counseling, and result disclosure.

• Committee Opinion #800 (2020): Hereditary Cancer Syndromes and Risk Assessment

OB-GYNs should identify patients who meet criteria for cancer genetic testing and refer for counseling/testing.

ACMG (American College of Medical Genetics and Genomics)

• ACMG 2021 Carrier Screening Recommendations

Pan-ethnic expanded carrier screening is a valid approach; minimum of 94 conditions if using exome-based methods.

• ACMG SF v3.2 (Secondary Findings)

When performing exome or genome sequencing, laboratories should report pathogenic/likely pathogenic variants in 73 medically actionable genes (v3.2, 2023 list). This is relevant when an insurer denies whole-exome sequencing (WES) as "too broad"—the ACMG framework ensures clinical utility.

CMS National Coverage Determination 90.2 (Next-Generation Sequencing)

Effective March 16, 2018, Medicare covers FDA-approved or -cleared NGS-based in vitro companion diagnostic tests for patients with advanced cancer (recurrent, relapsed, refractory, metastatic, or stage III/IV). The test must be ordered by a treating physician and used to guide therapy selection. This NCD means that Medicare Advantage plans and, by extension, many commercial policies adopt the same standard. If your FoundationOne CDx, Tempus xT, or Guardant360 CDx was ordered to identify targetable mutations in metastatic NSCLC, advanced breast cancer, or metastatic colorectal cancer, CMS NCD 90.2 is your anchor citation.

MolDX Local Coverage Determination L39167 (MRD Testing)

Several Medicare Administrative Contractors (Palmetto, Noridian) have adopted MolDX LCD L39167 covering circulating-tumor-DNA minimal-residual-disease (MRD) testing (e.g., Signatera, Guardant Reveal) in patients with solid tumors after curative-intent treatment, to guide adjuvant therapy and surveillance. Evidence base includes Reinert et al. Nature Medicine 2019 (colorectal MRD); Bratman et al. Cancer Discovery 2020 (head/neck); Henriksen et al. JCO 2022 (colorectal adjuvant de-escalation). If you are denied MRD monitoring post-surgery or post-chemo, cite MolDX L39167 and these pivotal trials.

Key Trials and Evidence

• Reinert et al., Nature Medicine 2019: Validated circulating tumor DNA (ctDNA) MRD detection in stage I–III colorectal cancer; MRD positivity predicts recurrence months before imaging.
• ACOG Practice Bulletin #226 (2020 update): Shifted cfDNA from high-risk-only to universal offer.
• Turnbull et al., NEJM 2018: Identified PALB2, ATM, and CHEK2 as moderate-penetrance breast-cancer genes, bolstering the case for multi-gene panels beyond BRCA1/2.
• Hu et al., JAMA 2021: Showed that multi-gene panel testing in unselected breast-cancer patients finds pathogenic variants in 9–10 %, with half in non-BRCA genes.

---

How to Argue Against Each Denial Reason

1. Fighting "Does Not Meet Medical Necessity Criteria"

Concrete steps:

• Obtain the specific internal policy. Call your insurer's provider line or submit a written request for the medical-policy bulletin that governed the denial (e.g., "UnitedHealthcare Genetic Testing Policy 2024-001," "Aetna Clinical Policy Bulletin 0140," "Cigna Coverage Policy 0052"). By law, you are entitled to the criteria used.

• Map your facts to NCCN criteria—by name and number. If you have breast cancer diagnosed at age 42, write: "Patient meets NCCN BOP-2 (breast cancer ≤45 years), which is a standalone, automatic indication for multi-gene hereditary-cancer panel testing per NCCN Guidelines v3.2024." If your mother had ovarian cancer at 52 and you're requesting testing, cite: "Patient has one first-degree relative with epithelial ovarian cancer; meets NCCN BOP-A, warranting germline panel."

• Invoke USPSTF Grade B + ACA §2713 if applicable. For women meeting personal/family/ancestry risk factors for BRCA, write: "The USPSTF (2019) assigns a B recommendation to BRCA risk assessment and testing for women with these risk factors. Under ACA §2713 and 45 CFR §147.130, this is a mandated preventive service that must be covered without cost-sharing in non-grandfathered plans. Denial violates federal preventive-services requirements."

• Challenge outdated criteria. If the denial letter cites a 2017 version of a guideline and the current 2024 version broadened indications, point that out explicitly: "Insurer's policy references NCCN 2017, which has been superseded by three major updates. Current NCCN v3.2024 explicitly includes [your criterion]."

• Provide a three-generation pedigree if family history is at issue. Attach a simple table or diagram (maternal grandfather: prostate cancer age 60; mother: breast cancer age 48; maternal aunt: ovarian cancer age 55) to demonstrate that you meet Amsterdam II (for Lynch) or NCCN BOP-A/B thresholds. Benefit managers often deny based on incomplete family-history documentation.

2. Fighting "Investigational / Experimental" (Tumor Profiling, MRD, WES/WGS)

Concrete steps:

• Cite CMS NCD 90.2 by name. "FoundationOne CDx is an FDA-approved companion diagnostic. CMS National Coverage Determination 90.2 (effective March 16, 2018) mandates Medicare coverage of FDA-approved/cleared NGS tests for beneficiaries with advanced cancer when used to guide therapy. Patient has metastatic non–small cell lung cancer (stage IV); FoundationOne was ordered to identify actionable mutations (EGFR, ALK, ROS1, BRAF, MET ex14, RET, NTRK, KRAS G12C) per NCCN NSCLC Guidelines v2.2024, which list comprehensive molecular profiling as Category 1 (highest-level evidence). This is neither investigational nor experimental—it is the standard of care."

• Cite tumor-specific NCCN biomarker mandates. NCCN Colon, Rectal, NSCLC, Melanoma, and other guidelines specify which biomarkers must be tested and when. Quote the relevant page: "NCCN Non–Small Cell Lung Cancer Guidelines (v2.2024, page NSCL-8) state: 'Broader molecular profiling is recommended to identify rare driver mutations.' Denial of comprehensive NGS contradicts NCCN Category 1 recommendation."

• For MRD testing, cite MolDX LCD L39167 + pivotal trials. "Signatera ctDNA MRD assay is covered under MolDX Local Coverage Determination L39167 for post-treatment surveillance in solid tumors. Patient completed curative resection and adjuvant chemotherapy for stage III colon cancer; MRD monitoring is used per Reinert et al., Nature Medicine 2019 and endorsed in ASCO 2023 provisional clinical opinion to detect recurrence earlier than imaging and guide treatment intensification. Test is not experimental—it is an FDA-breakthrough-designated, Medicare-covered, evidence-based surveillance tool."

• For WES/WGS in pediatric or rare disease, cite ACMG standards. "Patient is a 3-year-old with global developmental delay, dysmorphic features, and normal chromosomal microarray. ACMG 2021 technical standards recognize whole-exome sequencing as first-tier diagnostic test in patients with suspected Mendelian disorder when initial testing is non-diagnostic. Diagnostic yield is 25–40 % (Srivastava et al., Genetics in Medicine 2019). This is the recognized standard of care in pediatric genetics, not experimental."

3. Fighting "Single-Gene Test Sufficient; Multi-Gene Panel Not Necessary"

Concrete steps:

• Emphasize NCCN's explicit recommendation for panels. "NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (v3.2024) states on page BOP-1: 'Multi-gene panel testing, rather than single-syndrome testing, is recommended as the preferred approach.' Limiting patient to BRCA1/2 testing ignores moderate-penetrance genes—PALB2, ATM, CHEK2, BARD1—that carry 20–40 % lifetime breast-cancer risk and specific management recommendations (enhanced MRI screening, risk-reducing surgery, PARP-inhibitor eligibility)."

• Cite evidence that single-gene testing misses actionable variants. "Hu et al., JAMA 2021, found that in unselected breast-cancer patients, ~50 % of pathogenic variants occurred in non-BRCA genes. Turnbull et al., NEJM 2018, established PALB2 as high-penetrance (35 % lifetime risk by age 70) and ATM/CHEK2 as moderate-penetrance. Denying panel testing means patient and relatives will miss actionable findings that alter surveillance and prevention."

• Document that cost difference is minimal. Multi-gene panels today cost insurers roughly the same as—or even less than—serial single-gene tests, because NGS platforms sequence multiple genes simultaneously. If the insurer forces BRCA-only and the result is negative, you'd then need to order PALB2, then ATM, etc., multiplying claims and delaying care.

4. Fighting "Patient Does Not Meet High-Risk Criteria" (NIPT, Carrier Screening)

Concrete steps for NIPT:

• Cite ACOG #226/232 (2020) directly. "American College of Obstetricians and Gynecologists Practice Bulletin #232 and Committee Opinion #226 (reaffirmed 2020) recommend that cell-free DNA screening be offered to all pregnant patients as a primary screen, regardless of maternal age or risk factors. Patient is 28 years old, singleton pregnancy, no prior aneuploidy—insurer's 'high-risk only' policy contradicts current ACOG guidance and denies patient access to the most sensitive first-trimester screen for trisomy 21 (detection rate >99 %)."

• Note that many state mandates and ACA-compliant plans cover NIPT. Some states (e.g., New York) explicitly require insurers to cover NIPT without prior authorization. Even without a state law, if your plan covers prenatal screening, it cannot arbitrarily exclude the most accurate method endorsed by ACOG.

Concrete steps for carrier screening:

• Cite ACOG #691. "ACOG Committee Opinion #691 (reaffirmed 2019) endorses both ethnicity-based and expanded pan-ethnic carrier screening, stating that offering a broader panel (up to 100+ conditions) is acceptable and increasingly standard. Insurer's limitation to cystic fibrosis, sickle cell, and Tay-Sachs contradicts current professional guidelines and deprives patient and partner of information about autosomal-recessive conditions (e.g., spinal muscular atrophy, fragile X premutation, hemoglobinopathies beyond sickle cell) that affect reproductive decision-making."

5. Fighting Procedural Denials (No Prior Auth, No Genetic Counselor)

Concrete steps:

• Document emergent or clinically appropriate circumstances. "Patient presented with newly diagnosed metastatic colorectal cancer; oncologist ordered FoundationOne CDx at the time of diagnosis to identify MSI-high status (which contraindicates fluoropyrimidine monotherapy and indicates checkpoint-inhibitor eligibility) and KRAS/BRAF mutations prior to first-line treatment decision. Waiting for a multi-week prior-authorization process would have delayed life-saving systemic therapy. Under [state] insurance law and the plan's own urgent-care exception, prior authorization may be waived when delay would jeopardize health."

• Show that the ordering provider meets qualifications. "Test was ordered by a board-certified medical oncologist / maternal-fetal medicine specialist / certified genetic counselor [credential], who is qualified under NCCN and ACMG standards to order and interpret genetic testing. Plan's requirement for separate genetic-counselor involvement is not evidence-based when the ordering clinician has appropriate expertise."

• Offer to complete genetic counseling retrospectively. Some plans will approve on appeal if you agree to post-test genetic counseling. Include a letter from a genetic counselor stating willingness to provide counseling and offering dates.

---

What We Do

We turn these arguments into physician-ready appeal letters in minutes. You answer a short intake (test name, clinical indication, family history, CPT codes, denial reason), and our system generates a 1.5–2 page letter that cites the exact NCCN criterion (by number), the relevant USPSTF/ACOG/ACMG/CMS policy (with version and year), and the pivotal trials that anchor your case. The letter is written for your oncologist, genetic counselor, OB-GYN, or cardiologist to review, customize with patient-specific details, sign, and submit on letterhead. We do not give medical or legal advice—we give you the infrastructure to fight back with the evidence that insurers are contractually obligated to follow.

---

Sources

1. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2024. National Comprehensive Cancer Network, 2024. https://www.nccn.org/guidelines/category_2

2. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2024. National Comprehensive Cancer Network, 2024.

3. U.S. Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer. JAMA 2019;322(7):652–665. [Grade B recommendation]

4. American College of Obstetricians and Gynecologists. Practice Bulletin No. 226: Screening for Fetal Chromosomal Abnormalities. Obstet Gynecol 2020;136:e48–e69. [Reaffirmed 2020; universal cfDNA offer]

5. American College of Obstetricians and Gynecologists. Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstet Gynecol 2017;129:e41–e55. [Reaffirmed 2019]

6. American College of Obstetricians and Gynecologists. Committee Opinion No. 800: Hereditary Cancer Syndromes and Risk Assessment. Obstet Gynecol 2020;135:e73–e84.

7. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) 90.2: Next Generation Sequencing (NGS). Effective March 16, 2018. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=372

8. MolDX®. Local Coverage Determination L39167: MolDX: Minimal Residual Disease Testing Using Circulating Tumor DNA. Palmetto GBA and Noridian, 2023.

9. Reinert T et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol 2019;5(8):1124–1131. [Pivotal MRD validation]

10. Turnbull C et al. Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. N Engl J Med 2018;378:1805–1815. [Moderate-penetrance gene evidence]

11. Hu C et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. JAMA 2021;325(5):439–449. [Multi-gene panel utility]

12. American College of Medical Genetics and Genomics. ACMG SF v3.2 for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2023 Update. Genet Med 2023;25(8):100866.

13. Srivastava S et al. Meta-analysis and Multidisciplinary Consensus Statement: Exome Sequencing Is a First-Tier Clinical Diagnostic Test for Individuals with Neurodevelopmental Disorders. Genet Med 2019;21(11):2413–2421. [WES/WGS in rare disease]

14. Affordable Care Act § 2713 and implementing regulation 45 CFR § 147.130(a)(1). Preventive services; USPSTF A and B recommendations must be covered without cost-sharing.